Earnings Feed
Start Free
|4Feb 3, 4:32 PM ET

Cheng Sohanya Roshan 4

Research Summary

AI-generated summary

Updated

Karyopharm (KPTI) EVP Cheng Sohanya Roshan Receives 32,415 RSUs

What Happened
Cheng Sohanya Roshan, EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc. (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The award was granted at $0.00 (RSUs convert one-for-one into common shares) and is reported as a grant (transaction code A) — not a market purchase or sale.

Key Details

  • Transaction date: January 31, 2026; filing date: February 3, 2026 (Form 4 accession 0001193125-26-035687). Filing appears to be within the normal Form 4 reporting window.
  • Grant amount: 32,415 RSUs; per the filing the acquisition price is $0.00 (award).
  • Vesting: 50% of the RSUs vest on January 31, 2027; the remaining 50% vest on January 31, 2028 (see footnote F1). RSUs convert 1-for-1 into common stock when vested.
  • Shares owned after transaction: not specified in the supplied filing details.
  • Notable footnote: F1 describes the RSU award and the two-date vesting schedule. No 10b5-1, tax-withholding sale, or cashless exercise noted.

Context
This was an equity compensation award to an executive (a routine corporate compensation action) rather than a buy or sell signal. RSU grants reflect compensation/retention and will only result in actual shares if and when the awards vest.